IP Library › Granted Patent US 12,390,397
Granted Patent B2
US 12,390,397 · App. 18/734,051 · Granted Aug 19, 2025

Infusion bag

Inventors: Torsten Brandenburger (Friedberg, DE); Beatrix Heuel-Hoemmen (Friedberg, DE)
Assignee: Fresenius Kabi Deutschland GmbH
A61J1/10A61J1/1406A61J1/1431A61J1/1481B32B3/08B32B27/08B32B27/302B32B27/32B32B2250/03B32B2250/246B32B2270/00B32B2274/00B32B2307/412B32B2307/51B32B2307/558B32B2307/5825B32B2439/46B32B2439/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,390,397
App. No.
18/734,051
Granted
Aug 19, 2025
Kind
B2
Abstract

A medical package is made from a multi-layer film and is filled with a medical liquid for infusion and/or for parenteral nutrition. The medical package has at least one weld seam and at least one inner layer of a matrix-phase polymer system, an intermediate layer of a matrix-phase polymer system, and an outer layer of a matrix-phase polymer system.

Claims (45)

1. A pharmaceutical product comprising an infusion bag containing a medical liquid, wherein the infusion bag comprises a multilayer film comprising:

an inner layer;

an outer layer comprising a styrene-ethylene/butylene-styrene block copolymer in a matrix of a polymer; and

an intermediate layer disposed between the inner layer and the outer layer, the intermediate layer comprising a styrene-ethylene/butylene-styrene block copolymer in a matrix of a polymer,

wherein a ratio, by weight, of styrene to ethylene and butylene of the outer layer is between 0.18 and 0.28, and

wherein a ratio, by weight, of styrene to ethylene and butylene of the intermediate layer is between 0.10 and 0.16.

2. The pharmaceutical product of claim 1 , wherein:

the ratio, by weight, of styrene to ethylene and butylene of the outer layer is between 0.20 and 0.24, and

the ratio, by weight, of styrene to ethylene and butylene of the intermediate layer is between 0.13 and 0.14.

3. The pharmaceutical product of claim 1 , wherein the ratio, by weight, of styrene to ethylene and butylene of the outer layer is greater than 1.5 times the ratio, by weight, of styrene to ethylene and butylene of the intermediate layer.

4. The pharmaceutical product of claim 1 , wherein the intermediate layer further comprises a styrene-isoprene-styrene block copolymer in the matrix of the polymer.

5. The pharmaceutical product of claim 1 , wherein:

the inner layer comprises a styrene-ethylene/butylene-styrene block copolymer in a matrix of a polymer,

a ratio, by weight, of styrene to ethylene and butylene of the inner layer is between 0.18 and 0.28.

6. The pharmaceutical product of claim 5 , wherein the ratio, by weight, of styrene to ethylene and butylene of the inner layer is greater than 1.5 times the ratio, by weight, of styrene to ethylene and butylene of the intermediate layer.

7. The pharmaceutical product of claim 5 , wherein a ratio, by weight, of styrene to ethylene and butylene of the inner layer is equal to the ratio, by weight, of styrene to ethylene and butylene of the outer layer.

8. The pharmaceutical product of claim 5 , wherein the polymer of the inner layer, the intermediate layer, and/or the outer layer is polypropylene.

9. The pharmaceutical product of claim 5 , wherein the polymer of the inner layer and the intermediate layer is a polypropylene random copolymer and the polymer of the outer layer is a polypropylene homopolymer.

10. The pharmaceutical product of claim 9 , wherein the ratio, by weight, of styrene to ethylene and butylene of (i) the inner layer is between 0.20 and 0.24, (ii) the intermediate layer is between 0.13 and 0.14, and (iii) the outer layer is between 0.20 and 0.24.

11. The pharmaceutical product of claim 10 , wherein the medical liquid comprises at least one of sterile water, a saline solution, a carbohydrate solution, a solution at least one of sterile water, a saline solution, a carbohydrate solution, a solution, emulsion and/or suspension with nutrients for parenteral nutrition, a colloid solution, or a premix comprising an active ingredient.

12. The pharmaceutical product of claim 1 , wherein the medical liquid comprises at least one of sterile water, a saline solution, a carbohydrate solution, a solution, emulsion and/or suspension with nutrients for parenteral nutrition, a colloid solution, or a premix comprising an active ingredient.

13. The pharmaceutical product of claim 1 , wherein the infusion bag is a multi-chamber bag, wherein each chamber is separated from one another by an inner seam.

14. The pharmaceutical product of claim 13 , wherein the multi-chamber bag comprises three chambers, and the medical liquid in each chamber comprises a solution, emulsion or suspension with nutrients for parenteral nutrition.

15. The pharmaceutical product of claim 1 , wherein the multilayer film has a yield strength above 5 N/mm 2 and/or below 15 N/mm 2 and an elongation upon reaching the yield strength above 10% and/or below 30% measured according to International Organization for Standardization (ISO) 527 (Version 2012-06).

16. The pharmaceutical product of claim 1 , wherein the infusion bag comprises two of the multilayer film welded to one another at a longitudinal weld seam and a transverse weld seam.

17. The pharmaceutical product of claim 16 , wherein the infusion bag comprises a port welded in one of the longitudinal weld seam or the transverse weld seam.

18. The pharmaceutical product of claim 16 , wherein the multilayer film is configured to be expanded in a region of one of the longitudinal weld seam or the transverse weld seam to at least 150% of the length of the region without tearing.

19. A pharmaceutical product comprising a medical liquid contained within an infusion bag, wherein the infusion bag comprises a multilayer film comprising:

an inner layer, an outer layer, and an intermediate layer disposed between the inner layer and the outer layer, wherein each of the inner layer, the outer layer, and the intermediate layer comprises a styrene-ethylene/butylene-styrene block copolymer in a matrix of a polymer,

wherein a ratio, by weight, of styrene to ethylene and butylene of the inner layer and the outer layer is between 0.18 and 0.28,

wherein a ratio, by weight, of styrene to ethylene and butylene of the intermediate layer is between 0.10 and 0.16, and

wherein the polymer of the inner layer and the intermediate layer is a polypropylene random copolymer and the polymer of the outer layer is a polypropylene homopolymer.

20. A pharmaceutical product comprising a medical liquid contained within an infusion bag, wherein the infusion bag comprises a multilayer film comprising:

an inner layer, an outer layer, and an intermediate layer disposed between the inner layer and the outer layer, wherein each of the inner layer, the outer layer, and the intermediate layer comprises a styrene-ethylene/butylene-styrene block copolymer in a matrix of a polymer,

wherein a ratio, by weight, of styrene to ethylene and butylene of the inner layer and the outer layer is between 0.18 and 0.28,

wherein a ratio, by weight, of styrene to ethylene and butylene of the intermediate layer is between 0.10 and 0.16,

wherein the polymer of the inner layer and the intermediate layer is a polypropylene random copolymer and the polymer of the outer layer is a polypropylene homopolymer, and

wherein the medical liquid comprises at least one of a sterile water, a saline solution, a carbohydrate solution, a solution, emulsion and/or suspension with nutrients for parenteral nutrition, a colloid solution, or a premix comprising an active ingredient.

21. The pharmaceutical product of claim 20 , wherein the medical liquid consists essentially of the sterile water.

22. The pharmaceutical product of claim 20 , wherein the medical liquid consists essentially of the saline solution.

23. The pharmaceutical product of claim 20 , wherein the medical liquid consists essentially of the carbohydrate solution.

24. The pharmaceutical product of claim 20 , wherein the medical liquid consists essentially of the solution, emulsion and/or suspension with nutrients for parenteral nutrition.

25. The pharmaceutical product of claim 20 , wherein the medical liquid consists essentially of the colloid solution.

26. The pharmaceutical product of claim 20 , wherein the medical liquid consists essentially of the premix comprising the active ingredient.

27. The pharmaceutical product of claim 26 , wherein the active ingredient is paracetamol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2025
From: BRANDENBURGER, TORSTEN; HEUEL-HOEMMEN, BEATRIX
To: FRESENIUS KABI DEUTSCHLAND GMBH
Reel/Frame 070865/0236 →
Priority Claims (1)
EP 18189930 · Aug 21, 2018 · regional
Continuity (2)
Continuation 17253424
Related Publication 20250017818A1 · Jan 16, 2025
References Cited (28)
US 5431496A · Balteau · 1995 [cited by examiner]
US 5783269A · Heilmann et al. · 1998 [cited by applicant]
US 5928744A · Heilmann et al. · 1999 [cited by applicant]
US 5998019A · Rosenbaum et al. · 1999 [cited by applicant]
US 6004311A · Heilmann et al. · 1999 [cited by applicant]
US 6004636A · Nicola et al. · 1999 [cited by applicant]
US 6017598A · Kreischer et al. · 2000 [cited by applicant]
US 6461696B1 · Ling et al. · 2002 [cited by applicant]
US 9248625B2 · Kreischer et al. · 2016 [cited by applicant]
US 12005026B2 · Brandenburger · 2024 [cited by examiner]
US 20110249916A1 · Herrenbauer et al. · 2011 [cited by applicant]
US 20130072895A1 · Kreischer et al. · 2013 [cited by applicant]
AU 515643 · 1981 [cited by applicant]
CL 199401683 · 1994 [cited by applicant]
CL 199700643 · 1997 [cited by applicant]
CL 200100293 · 2001 [cited by applicant]
CL 201101163 · 2011 [cited by applicant]
CL 201702860 · 2017 [cited by applicant]
JP 4086421 · 2008 [cited by applicant]
KR 20010076525 · 2001 [cited by applicant]
KR 20030046120 · 2003 [cited by applicant]
WO 199737628 · 1997 [cited by applicant]
WO 2011128185 · 2011 [cited by applicant]
WO 2016180869 · 2016 [cited by applicant]
Asahi Kasei Corporation, Tuftec H Series, P Series Selectively Hydrogenated Type, M Series Acid or Amine Modified Type, Hydrogenated Styrenic Thermoplastic Elastomer (SEBS), Apr. 2016 (20 pages). [cited by applicant]
Larsson et al., Leachable/extractable issues in a pharmacy setting, Hospital Pharmacy Europe, May 28, 2015 (10 pages). [cited by applicant]
Septon™ product literature, Kuraray (Year: 2023). [cited by applicant]
Tuftec™ product literature, Asahi Kasei (Year: 2015). [cited by applicant]